A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Andrea Wang-Gillam, William P. Tew, MacE L. Rothenberg, Jakob Dupont, Wendy Cooper, Lars Sternas, Giliane Buzenet, Jeffrey A. Sosman, David R. Spriggs, Albert Craig Lockhart

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Summary: Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.

Original languageEnglish (US)
Pages (from-to)1958-1961
Number of pages4
JournalInvestigational New Drugs
Volume30
Issue number5
DOIs
StatePublished - Oct 2012
Externally publishedYes

Keywords

  • Aflibercept
  • Angiogenesis inhibitor
  • Phase I study
  • Subcutaneously administration

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A phase i study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors'. Together they form a unique fingerprint.

Cite this